Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer.
HER2 positive breast cancer
efficacy
long-term safety
real-world settings
trastuzumab
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 Feb 2019
18 Feb 2019
Historique:
received:
22
01
2019
revised:
14
02
2019
accepted:
15
02
2019
entrez:
21
2
2019
pubmed:
20
2
2019
medline:
20
2
2019
Statut:
epublish
Résumé
Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Results from several long-term (>5 years) safety analyses have been recently published, with the inherent evidence substantially confirming the findings from previous trials. The clinical experience gained over the years in the use of trastuzumab has also fueled a number of observational studies focused on the effectiveness of this drug in the real-world settings. We herein reviewed the evidence available from tree major databases, namely, PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), to explore and critically discuss key issues related to the long-term safety and effectiveness of trastuzumab in clinical practice.
Identifiants
pubmed: 30781624
pii: jcm8020254
doi: 10.3390/jcm8020254
pmc: PMC6406268
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Clin Breast Cancer. 2004 Apr;5(1):63-9
pubmed: 15140287
J Clin Oncol. 2005 Jun 1;23(16):3676-85
pubmed: 15738535
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Cancer. 2007 Sep 15;110(6):1195-200
pubmed: 17647266
BMC Cancer. 2007 Aug 08;7:153
pubmed: 17686164
J Clin Oncol. 2009 Dec 1;27(34):5685-92
pubmed: 19884557
Lancet. 2010 Jan 30;375(9712):377-84
pubmed: 20113825
Expert Opin Drug Saf. 2010 Mar;9(2):335-46
pubmed: 20175700
J Clin Oncol. 2010 Apr 20;28(12):2024-31
pubmed: 20308670
J Clin Oncol. 2010 Jul 20;28(21):3416-21
pubmed: 20530275
J Clin Oncol. 2011 Sep 1;29(25):3351-7
pubmed: 21788566
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Exp Clin Cardiol. 2011 Fall;16(3):70-4
pubmed: 22065936
Breast Cancer Res Treat. 2012 Oct;135(3):875-83
pubmed: 22923238
J Clin Oncol. 2012 Nov 1;30(31):3792-9
pubmed: 22987084
J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40
pubmed: 23604446
Oncologist. 2013;18(5):501-10
pubmed: 23652380
Breast Cancer Res Treat. 2014 May;145(1):143-53
pubmed: 24682674
J Clin Oncol. 2014 Jul 10;32(20):2159-65
pubmed: 24912899
Breast Cancer Res Treat. 2014 Oct;147(3):599-607
pubmed: 25234842
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Future Oncol. 2015;11(10):1493-500
pubmed: 25708426
Trends Pharmacol Sci. 2015 Jun;36(6):326-48
pubmed: 25895646
Breast. 2015 Aug;24(4):376-83
pubmed: 25913287
Oncologist. 2015 Aug;20(8):856-63
pubmed: 26099745
PLoS One. 2015 Sep 04;10(9):e0136731
pubmed: 26340098
J Clin Oncol. 2016 Feb 20;34(6):581-7
pubmed: 26392097
Breast. 2015 Dec;24(6):751-7
pubmed: 26456898
J Natl Cancer Inst. 2015 Oct 16;108(1):null
pubmed: 26476433
Eur J Cancer. 2016 Jan;52:41-9
pubmed: 26630533
Oncotarget. 2016 Apr 5;7(14):17932-44
pubmed: 26910921
Oncologist. 2016 May;21(5):555-62
pubmed: 27009939
J Cell Physiol. 2016 Nov;231(11):2541-7
pubmed: 27187274
Pharmacoeconomics. 2016 Oct;34(10):1039-50
pubmed: 27207252
Oncotarget. 2017 Jan 10;8(2):2069-2075
pubmed: 27906683
Med Sci Monit. 2016 Dec 21;22:5035-5040
pubmed: 28000658
Oncologist. 2017 Feb;22(2):131-138
pubmed: 28174294
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):22-27
pubmed: 28469333
Oncologist. 2017 Nov;22(11):1333-1338
pubmed: 28798274
J Clin Oncol. 2017 Dec 10;35(35):3942-3948
pubmed: 29072977
Breast. 2018 Apr;38:7-13
pubmed: 29172171
BMC Cancer. 2018 Mar 15;18(1):295
pubmed: 29544445
Breast Cancer Res Treat. 2018 Aug;171(1):151-159
pubmed: 29736743
Breast Cancer Res Treat. 2019 Feb;174(1):187-196
pubmed: 30506110
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106